CBUS

Cibus, Inc.'s stock price has been impacted by earnings reports, public offerings, board appointments, and business developments in the past six months. Earnings reports included the 3Q25 Financial Results Conference Call, the announcement of financial results for the fourth quarter ended December 31, 2025, and the upcoming First Quarter 2026 Financial Results. Public offerings in January and March 2026 aimed to strengthen the balance sheet and support trait development. Craig Wichner and Thomas Urban were appointed to the Board of Directors. Business developments included positive field trial results for HT2 edited canola, the first customer payment from its Sustainable Ingredients program, and the transfer of gene-edited herbicide tolerance materials in rice to its partner Interoc. Cibus was upgraded to a Zacks Rank #2 (Buy), and analysts have adjusted price targets. The stock has experienced high volatility, and shareholders have been substantially diluted. Cibus's stock was trading at $1.74 at the start of the year and has since decreased by 17.2% to $1.44 as of May 9, 2026.